MTRI
Mentari Therapeutics, Inc. is a biotechnology company, which engages in developing therapies for migraine prevention. Its portfolio includes MT-001 and MT-002. The company was founded on June 13, 2025 and is headquartered in Waltham, MA.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -4.30 | $0 | -$1M |
| 2026 Q4 | -14.30 | $2.1B | -$3M |
| 2026 Q3 | -7.30 | $0 | -$2M |
| 2025 Q2 | -5.21 | $820,000 | -$3M |
| 2025 Q1 | -6.08 | $1M | -$2M |
| 2025 Q4 | -12.20 | $2M | -$2M |
| 2025 Q3 | -19.40 | $1M | -$2M |
| 2024 Q2 | -36.40 | $1M | -$3M |